

IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Original): The monosodium salt of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid in an amorphous form, having the X-ray diffraction pattern showing characteristic broad obtuse peak at  $2\theta$  angles ranging from 15 to 25 °, and, optionally, two sharp peaks at  $2\theta$  angles of 5.856 and 6.99 °.

Claim 2 (Currently Amended): The substance according to claim 1, ~~characterized by having a~~ characteristic broad obtuse peak at  $2\theta$  angles ranging from 17.4 to 20.2 °.

Claim 3 (Currently Amended): The substance according to claim 1, ~~characterized by having bands at 3084, 2936, 1633, 1051 and 120 cm<sup>-1</sup> in the Raman spectrum and [[by]] expanded bands at 139, 125, 75 and 37 ppm in the <sup>13</sup>C CP MAS NMR spectrum.~~

Claim 4 (Currently Amended): The substance according to claim 1, ~~characterized by having two sharp peaks at  $2\theta$  angles of 5.856 and 6.99 ° and a broad band at  $2\theta$  17.6 ° and a plateau without peaks between  $2\theta$  angles of 23 - 35 °.~~

Claim 5 (Currently Amended): The substance according to claim 4, ~~characterized by having expanded bands at 3085, 2786, 2379, 1561, 1212 and 809 cm<sup>-1</sup> in the IR spectrum and [[by]] expanded bands at 137.9, 124.5, 73.6, 36.8 ppm in the <sup>13</sup>C CP MAS NMR spectrum.~~


Claim 6 (Currently Amended): The substance according to claim 3 or 4, having the water content of 0 to 7 % by weight.

Claim 7 (Original): The substance according to claim 6, having the water content of 4 to 7 % by weight.

Claim 8 (Original): The substance according to claim 3, having the water content of 7 to 10 % by weight.

Claim 9 (Original): The substance according to claim 8, having the water content of 9 to 10 % by weight.

Claim 10 (Currently Amended): A method of preparation of preparing the substance according of claim 3, ~~characterized in that comprising heating~~ 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid of formula I



in the crystalline form ~~is heated at to a temperature of~~ 60 to 200 °C for 1 to 48 hours.

Claim 11 (Currently Amended): The method according to claim 10, characterized in that wherein the crystalline substance of formula I is used in the form of pentahydrate.

Claim 12 (Currently Amended): The method according to claim 10 or 11, characterized in that wherein the crystalline substance of formula I is heated [[at]] to a temperature of 120 to 140 °C.

Claim 13 (Currently Amended): The method according to claim 11, characterized in that wherein the pentahydrate of the substance of formula I is heated [[at]] to a temperature of 130 °C for 4 to 8 hours.

Claim 14 (Currently Amended): A method of preparation of preparing the substance according of claim 4, characterized in that comprising heating 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid (formula I) in the crystalline form is heated at to a temperature of 50 to 120 °C, under a pressure of 10 to 100 kPa, for 1 to 48 hours.

Claim 15 (Currently Amended): The method according to claim 14, characterized in that wherein the crystalline substance of formula I is used in the form of pentahydrate.

Claim 16 (Currently Amended): The method according to claim 14 or 15, characterized in that wherein the crystalline substance of formula I is heated [[at]] to a temperature of 50 to 100 °C, the temperature being at a gradually elevated rate.

Claim 17 (Currently Amended): The method according to claim 15, characterized in that wherein the pentahydrate of the substance of formula I is heated at 110 °C for 18 to 48 hours.

Claim 18 (Currently Amended): The method according to claim 15 or 16, ~~characterized in that wherein said~~ heating is carried out under a reduced pressure, ~~preferably of~~ at 10 to 30 kPa.

Claim 19 (Currently Amended): A method of ~~preparation of~~ preparing the substance according of claim 8, ~~characterized in that comprising~~ spray drying a solution of risedronate sodium ~~is spray dried~~ in a stream of [[a]] gas.

Claim 20 (Currently Amended): The method according to claim 19, ~~characterized in that wherein~~ the spray drying is applied to a solution of risedronate sodium having the concentration of 1 to 250 g/l in water, optionally in a mixture of water with a C1 to C4 alcohol.

Claim 21 (Currently Amended): The method according to claim 19 or 20, ~~characterized in that wherein~~ the solution of risedronate is heated to 20 to 100 °C before ~~being fed~~ feeding to the drier.

Claim 22 (Currently Amended): The method according to ~~any of claims~~ claim 19, 20 and 21, ~~characterized in that wherein~~ the drying is carried at a temperature of the feed nozzle region of the drier ranging from 70 to 220 °C.

Claim 23 (Currently Amended): The method according to ~~any of claims~~ claim 19[-22], ~~characterized in that wherein~~ the gas outlet from the spray dryer has a temperature of 40 to 150 °C.

Claim 24 (Currently Amended): The method according to claim 22 or 23, characterized in that wherein the temperature of the outlet gases from the drier is maintained at 50 to 70 °C.

Claim 25 (Currently Amended): A pharmaceutical formulation, characterized in that it contains the comprising an active substance in the amorphous form according to of claim 1 in amorphous form and at least one other pharmaceutically utilizable substance acceptable carrier.

Claim 26 (Currently Amended): The pharmaceutical formulation according to claim 25, characterized in that it wherein the carrier is a tablet containing a combination of mannitol and microcrystalline cellulose in tablet form.

Claim 27 (Currently Amended): The pharmaceutical formulation according to claim 25 or 26, characterized in that it contains comprising 5 or 35 mg of the active substance.